RE:RE:RE:RE:Good times aheadConsidering that PDT is not an established technology yet in oncology, our time will come on clearer data that leaves no doubt, that shows where we can fit over competition.
We're getting closer and closer to that moment and it would already have happened if our first 12 Ph. 2 patients would have been properly dosed. But this issue could even be seen as positive if the FDA wants to make a clear distinction between the first 12 and the rest, especially that they've been informed Sept. 2021 that Ph. 1b patients #5 and #6 have been cancer free for 540 consecutive days. It could show the difference between 1 dose versus 2 doses on a larger pool of patients than just Ph. 1b patients #5 and #6.